These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12162703)

  • 21. Antisense oligonucleotide therapy in urology.
    Kausch I; Böhle A
    J Urol; 2002 Jul; 168(1):239-47. PubMed ID: 12050550
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The new antibiotics.
    Breithaupt H
    Nat Biotechnol; 1999 Dec; 17(12):1165-9. PubMed ID: 10585711
    [No Abstract]   [Full Text] [Related]  

  • 23. A status update of modified oligonucleotides for chemotherapeutics applications.
    Sanghvi YS
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense strategies.
    Crooke ST
    Curr Mol Med; 2004 Aug; 4(5):465-87. PubMed ID: 15267220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of antisense oligonucleotides in functional genomics and target validation.
    Ravichandran LV; Dean NM; Marcusson EG
    Oligonucleotides; 2004; 14(1):49-64. PubMed ID: 15104896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
    Henry SP; Geary RS; Yu R; Levin AA
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Locked nucleic acid holds promise in the treatment of cancer.
    Frieden M; Ørum H
    Curr Pharm Des; 2008; 14(11):1138-42. PubMed ID: 18473860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic potential of antisense oligonucleotides.
    Sharma HW; Narayanan R
    Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.
    Nyce J
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisense 98: work in progress.
    Nat Biotechnol; 1998 Dec; 16(13):1319-21. PubMed ID: 9853610
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense oligonucleotide drug design.
    Schiavone N; Donnini M; Nicolin A; Capaccioli S
    Curr Pharm Des; 2004; 10(7):769-84. PubMed ID: 15032702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA drug design for cancer therapy.
    Cho-Chung YS
    Curr Pharm Des; 2005; 11(22):2811-23. PubMed ID: 16101439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structural modifications of antisense oligonucleotides.
    Urban E; Noe CR
    Farmaco; 2003 Mar; 58(3):243-58. PubMed ID: 12620420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.